ABT-737

Research use only, not for human use.

A BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively.

A BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; shows no inhibition against Mcl-1, Bcl-B or Bfl-1; induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway; exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models.Ovarian Cancer Phase 2 Clinical

ABT737;ABT 737

Angiogenesis

Bcl-2

Bcl-2;Bcl-B;Bcl-w;Bcl-xL;Bfl-1

Cancer

Ovarian Cancer

852808-04-9

813.43

C42H45ClN6O5S2

>98% (HPLC)

10 mM in DMSO

O=C(NS(=O)(C1=CC=C(N[C@H](CCN(C)C)CSC2=CC=CC=C2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=CC=CC=C5C6=CC=C(Cl)C=C6)CC4)C=C3

Benzamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-

(-20℃)

With Ice Pack

≥ 2 years